FIELD: medicine.
SUBSTANCE: method involves applying composition based on receptor antagonist P substance and magnesium salt.
EFFECT: reduced hematoencephalic barrier permeability; reduced risk of vasogenic brain edema; prevented water accumulation in brain; smoothing consequences caused by reduced cognitive abilities.
23 cl, 2 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF RECEPTOR NK-1 ANTAGONISTS FOR TREATING CRANIOCEREBRAL AND SPINAL TRAUMAS OR NERVOUS TISSUE LESION | 2002 |
|
RU2304435C2 |
| MODULATION OF AQUAPORINS WITH RELAXIN | 2011 |
|
RU2564900C2 |
| METHOD FOR TREATMENT OF CEREBROVASCULAR BRAIN DISORDERS (OPTIONS) | 2017 |
|
RU2659674C1 |
| METHODS AND COMPOSITIONS FOR TREATING CRANIOCEREBRAL INJURY | 2016 |
|
RU2701565C1 |
| METHOD OF TREATING CEREBRAL OEDEMA IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASES | 2014 |
|
RU2539139C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MENTAL, BEHAVIOUR AND COGNITIVE DISORDERS | 2012 |
|
RU2488388C1 |
| METHODS OF NEURAL DISORDER TREATMENT WITH USING HEMATOPOIETIC GROWTH FACTORS | 2003 |
|
RU2353385C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING CONSEQUENCES OF CRANIOCEREBRAL INJURY AND METHOD FOR PRODUCTION THEREOF (EMBODIMENTS) | 2018 |
|
RU2693633C1 |
| COMPOSITIONS FOR TREATING CEREBRAL LESIONS | 2016 |
|
RU2710543C2 |
| EDARAVON COMBINATION FOR TREATING ISCHEMIC BRAIN INJURY | 2017 |
|
RU2693627C2 |
